ArticleInternational journal of nanomedicine2026
Zirconium-Doped Ceria Oxide Nanozymes Alleviate Allergic Rhinitis by Attenuating Oxidative Stress and Stabilizing Mast Cells.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oxidative stress is fundamental to the pathogenesis and progression of allergic rhinitis (AR) during mast cell (MC) degranulation. However, effective therapeutic strategies that target both oxidative stress and the degranulation process remain limited. We developed ultrasmall mPEG (2000)-PE-modified zirconium-doped cerium oxide nanoparticles (PEG-CZ NPs) with broad-spectrum reactive oxygen/nitrogen species (ROS/RNS) scavenging and intrinsic phosphatase-like activity and investigated their prophylactic efficacy in an ovalbumin (OVA)-induced mouse model of AR. Methods: PEG-CZ NPs were synthesized and characterized, and their superoxide dismutase-, catalase-, and phosphatase-like activities were assessed. Antioxidative and MC-stabilizing effects were examined in anti-DNP IgE-sensitized, DNP-HSA-challenged RBL-2H3 cells by measuring intracellular ROS/RNS, β-hexosaminidase (β-HEX) release, and transcriptomic changes. Prophylactic efficacy and biosafety were evaluated in OVA-induced AR mice following intranasal administration of PEG-CZ NPs (2 mg kg Results: The PEG-CZ NPs were ultrasmall and well dispersed and exhibited robust multienzyme-like activity, efficiently scavenging ROS (H Conclusion: PEG-CZ NPs alleviated AR by scavenging ROS/RNS and inhibiting MC degranulation. These findings support the use of PEG-CZ nanozymes as a promising prophylactic platform for AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.